COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 1060: Articles 10591-10600  | Next

Introduction and community transmission of SARS-CoV-2 lineage A.2.5 in Florida with novel spike INDELS
Schmedes, S. E., Azarian, T., Cella, E., Motes, J., Tekin, O., Weiss, J., Miller, N., Blanton, J.
10.1101/2021.12.03.21266538 — Posted: 2021-12-05
Disruptions in Care: Consequences of the COVID-19 Pandemic in a Children's Hospital
Diskin, C., Orkin, J., Dharmaraj, B., Agarwal, T., Parmar, A., Mc Naughton, K., Cohen, E., Sunderji, A., Faraoni, D., Fecteau, A., Fischer, J., Mahant, S., Friedman, J.
10.1101/2021.12.02.21266778 — Posted: 2021-12-05
The impact of the COVID-19 pandemic on children with medical complexity
Diskin, C., Buchanan, F., Cohen, E., Dewan, T., Diaczun, T., Gordon, M., Lee, E., Moore Hepburn, C., Major, N., Orkin, J., Patel, H., Gill, P.
10.1101/2021.12.02.21266765 — Posted: 2021-12-05
Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review
Vaughan, A. M., Duffell, E. F., Friedl, G. S., Lemos, D. S., Funk, T., Nardone, A., Valenciano, M., Subissi, L., Bergeri, I., Broberg, E., Penttinen, P., Pebody, R., Keramarou, M.
10.1101/2021.12.02.21266897 — Posted: 2021-12-05
Guillain-Barre Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
Hanson, K. E., Goddard, K., Lewis, N., Fireman, B., Myers, T. R., Bakshi, N., Weintraub, E., Donahue, J. G., Nelson, J. C., Xu, S., Glanz, J. M., Williams, J. T., Alpern, J. D., Klein, N. P.
10.1101/2021.12.03.21266419 — Posted: 2021-12-05 Discussion: Onsite
Comparing human and model-based forecasts of COVID-19 in Germany and Poland
Bosse, N. I., Abbott, S., Bracher, J., Hain, H., Quilty, B. J., Jit, M., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, , van Leeuwen, E., Cori, A., Funk, S.
10.1101/2021.12.01.21266598 — Posted: 2021-12-05
The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901.
Hsieh, S.-M., Chang, S.-c., Cheng, H.-Y., Shih, S.-R., Lien, C. E.
10.1101/2021.12.01.21267115 — Posted: 2021-12-05
Price-performance comparison of HEPA air purifiers and lower-cost MERV 13/14 filters with box fans for filtering out SARS-Cov-2 and other particulate aerosols in indoor community settings
Srikrishna, D.
10.1101/2021.12.04.21267300 — Posted: 2021-12-05
The Impact of COVID-19 on NO2 and PM2.5 Levels and Their Associations with Human Mobility Patterns in Singapore
Li, Y., Zhu, Y., Tan, J. Y. K., Teo, H. C., Law, A., Qu, D., Luo, W.
10.1101/2021.12.02.21267165 — Posted: 2021-12-05
Mental sequelae of the Covid-19 pandemic: Well-being one year into the crisis in children with and without complex medical histories and their parents
Ehrler, M., Hagmann, C. F., Kretschmar, O., Landolt, M. A., Latal, B., Wehrle, F. M.
10.1101/2021.12.05.21267236 — Posted: 2021-12-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).